Golnaz Vahedi

Golnaz Vahedi

Auto-generated profile, based on publicly available information

Golnaz Vahedi

Department of Genetics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2022 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
MFMaria Fasolino
Maria Fasolino
GSGregory W. Schwartz
Gregory W. Schwartz
APAbhijeet R. Patil
Abhijeet R. Patil
AMAanchal Mongia
Aanchal Mongia
MGMaria L. Golson
Maria L. Golson
GVGolnaz Vahedi
Golnaz Vahedi

1 February 2018 in Immunity
Verified
Journal Article
Closed access
JJJohn L. Johnson
John L. Johnson
GGGeorgios Georgakilas
Georgios Georgakilas
JPJelena Petrovic
Jelena Petrovic
MKMakoto Kurachi
Makoto Kurachi
SCStanley Cai
Stanley Cai
GVGolnaz Vahedi
Golnaz Vahedi

24 March 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
SYSora Yoon
Sora Yoon
ACAditi Chandra
Aditi Chandra
GVGolnaz Vahedi
Golnaz Vahedi
Architectural stripes tend to form at genomic regions harboring genes with salient roles in cell identity and function. Therefore, the accurate identification and quantification of these features are essential for understanding lineage-specific gene regulation. Here, we present Stripenn, an algorithm rooted in computer vision to systematically detect and quantitate architectural stripes from chromatin conformation measurements using various technologies. We demonstrate that Stripenn outperforms existing methods and highlight its biological applications in the context of B and T lymphocytes. By comparing stripes across distinct cell types and different species, we find that these chromatin features are highly conserved and form at genes with prominent roles in cell-type-specific processes. In summary, Stripenn is a computational method that borrows concepts from widely used image processing techniques to demarcate and quantify architectural stripes.

20 June 2022 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
WWWenliang Wang
Wenliang Wang
ACAditi Chandra
Aditi Chandra
NGNaomi Goldman
Naomi Goldman
SYSora Yoon
Sora Yoon
EFEmily K. Ferrari
Emily K. Ferrari
GVGolnaz Vahedi
Golnaz Vahedi

1 June 2022 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
NDNicolai M. Doliba
Nicolai M. Doliba
ARAndrea V. Rozo
Andrea V. Rozo
JRJeffrey Roman
Jeffrey Roman
WQWei Qin
Wei Qin
DTDaniel Traum
Daniel Traum
DSDoris A. Stoffers
Doris A. Stoffers
BACKGROUND. Multiple islet autoantibodies (AAbs) predict the development of type 1 diabetes (T1D) and hyperglycemia within 10 years. By contrast, T1D develops in only approximately 15% of individuals who are positive for single AAbs (generally against glutamic acid decarboxylase [GADA]); hence, the single GADA+ state may represent an early stage of T1D. METHODS. Here, we functionally, histologically, and molecularly phenotyped human islets from nondiabetic GADA+ and T1D donors. RESULTS. Similar to the few remaining β cells in the T1D islets, GADA+ donor islets demonstrated a preserved insulin secretory response. By contrast, α cell glucagon secretion was dysregulated in both GADA+ and T1D islets, with impaired glucose suppression of glucagon secretion. Single-cell RNA-Seq of GADA+ α cells revealed distinct abnormalities in glycolysis and oxidative phosphorylation pathways and a marked downregulation of cAMP-dependent protein kinase inhibitor β (PKIB), providing a molecular basis for the loss of glucose suppression and the increased effect of 3-isobutyl-1-methylxanthine (IBMX) observed in GADA+ donor islets. CONCLUSION. We found that α cell dysfunction was present during the early stages of islet autoimmunity at a time when β cell mass was still normal, raising important questions about the role of early α cell dysfunction in the progression of T1D. FUNDING. This work was supported by grants from the NIH (3UC4DK112217-01S1, U01DK123594-02, UC4DK112217, UC4DK112232, U01DK123716, and P30 DK019525) and the Vanderbilt Diabetes Research and Training Center (DK20593).

15 May 2023 in Nature Metabolism
Verified
Journal Article
Closed access
PDF file
APAbhijeet R. Patil
Abhijeet R. Patil
JSJonathan Schug
Jonathan Schug
ANAli Naji
Ali Naji
KKKlaus H Kaestner
Klaus H Kaestner
RFRobert B. Faryabi
Robert B. Faryabi
GVGolnaz Vahedi
Golnaz Vahedi